Very pleased to share this review on FGFR2b which is a key emerging biomarker in gastric and gastroesophageal #Cancer Looking forward to seeing those FORTITUDE 101 results soon 👀! Hopefully #ESMO25 in Berlin! Thanks 🙏 to all my co-authors! sciencedirect.com/science/articl…

🚨 Real-world data on neoadj. ICIs for dMMR/MSI colon cancer (n=32; 22 pembro, 10 nivo+ipi): esmoopen.com/article/S2059-… ▪️ pCR 42% | pMR: 64% ⚠️ G≥3 AEs: 19% (1 G5 myocarditis) 🔒 Signet ring & mucinous histo linked to resistance Lower response vs trials, but still solid

🚨 New review in Nature Reviews Cancer dives into the complexity of #SCLC: nature.com/articles/s4156… Highlights: ▪️Marked heterogeneity & plasticity ▪️NOTCH-driven NE↔non-NE shifts 💉 DLL3-targeted therapy emerging 🧬 Molecular subtypes (ASCL1, NEUROD1, POU2F3) & biomarker under study

First impressions😉

Colorectal Cancer Screening in Adults 45–49 🔗 jamanetwork.com/journals/jama/… 📊 RCT (n=20,509) tested 4 outreach strategies 📉 Active choice via portal: 14.5–17.4% 📈 Default mailed FIT: 26.2% (most effective) ⚠️ Screening still low → better engagement needed

Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial ascopubs.org/doi/10.1200/JC… This multicenter, single-arm phase II trial evaluated stereotactic radiosurgery/radiotherapy

#PallOnc study in Journal of Pain and Symptom Management (JPSM) It's been 15 years since #Temel secured early #pallonc as guideline #SoC. Despite this, only 8% ⁉️of U.S. pt got #ePC ⬆️ chance in #lcsm ⬇️ chance in #bcsm 🔗: jpsmjournal.com/article/S0885-… #supponc Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Cardinale B. Smith ASCO PallOnc Community of Practice

🧬 Prospective data on the impact of PAM50-based Prosigna in neoadj. planning for HR+/HER2– early breast cancer (n=54) esmoopen.com/article/S2059-… 🎯 Tx plan changed in 35.2% ▪️ Confidence ↑ in 83.7% of physicians ▪️ Anxiety ↓ in 62.5% of patients ✅ Prosigna may guide

💥 New Nature Reviews Cancer dives deep into #SCLC: nature.com/articles/s4156… ▪️Lineage shifts, immune evasion, epigenetic rewiring 🔬 Subtypes: ASCL1, NEUROD1, POU2F3, inflamed 💡 CDX, PDX, GEMMs to model complexity Cracking plasticity may unlock small cell victories 🏆 OncoAlert

Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade–resistant #melanoma : Final analysis from a phase 1b study buff.ly/YJosSOB This final analysis of a phase 1b, open-label, multicenter study

🆕 #ESMO guidelines for localized rectal cancer are here 🔗 annalsofoncology.org/article/S0923-… 🎯 Evidence-based + multidisciplinary expertise = practical algorithms for every step. In rectal cancer, it’s all about keeping our guidelines…tight 💪 #ColorectalCancer OncoAlert

💥🚨 Ph I trial of DLL3/CD3 T-cell engager obriktamig in SCLC & NECs (Journal of Clinical Oncology): ascopubs.org/doi/10.1200/JC… ▪️ n=168, 72% ≥2L, 51% prior ICI 🎯 ORR 23% (B2/B3 ≥90 µg/kg: 28%) ▪️ SCLC 21%, epNEC 27%, LCNEC-L 70% ⏱️ DoR 8.5 mo | ⚠️ CRS any grade: 57%, ≥G3: 3% Obriktamig may

Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy buff.ly/v90Gufj Large

Join us for the 44th Annual Congress of the European Society of Surgical Oncology (ESSO 44) European Society of Surgical Oncology (ESSO) Gothenburg, Sweden🇸🇪 15 to 17 October 2025 REGISTER HERE 👉 buff.ly/a5WaGmM We invite researchers, clinicians, and residents to attend and take part of the

🟠Perioperativd toripalimab plus CapeOX for MSI-H GC/EGJC NICE eClinicalMedicine – The Lancet Discovery Science ➡️cT3–4aNxM0 or cT2N + M0 ➡️4x-Surgery-4x ➡️16 patients ✅pCR: 80% ✅MPR: 93.3% 👉thelancet.com/journals/eclin… #cancer #oncology #gastric #MedX OncoAlert Nieves Martinez Lago MD PhD Eduardo Terán

🚨 Real-world ICI efficacy in MSI/dMMR BTC (n=48, 🇫🇷 cohort) ejcancer.com/article/S0959-… 🎯 mOS 40.9m | mPFS: 11.2m | ORR 36% | DCR 75% ⚠️ AEs Gr 3–4: 15% w/o chemo vs 50% w/ chemo ▪️ 48% had co-alterations (e.g. TP53, KRAS, CDKN2A/B) First-line chemo may not be needed—this

📋❓Should we withhold targeted cancer therapies or immunotherapy during RT? ✅ESMO - Eur. Oncology and ESTRO framework 👉thegreenjournal.com/article/S0167-… OncoAlert Dr. Nina Niu Sanford M. Bolton #cancer #oncology #MedX

🚬 A clear #carcinogen 👇🏽👇🏽

🚨 Weekly roundup curated by OncoAlert has something for everyone—from endocrine therapy and epNECs to Prosigna and KRAS resistance! A week that reminds us how far oncology reaches: across tumors, across targets, across tissues.   Truly a multi-cancer-ous collection! 💡